Browse ID2

Summary
SymbolID2
Nameinhibitor of DNA binding 2, dominant negative helix-loop-helix protein
Aliases GIG8; bHLHb26; cell growth-inhibiting gene 8; GIG8A; ID2H; DNA-binding protein inhibitor ID2; class B basic ......
Chromosomal Location2p25
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cytoplasm Nucleus
Domain PF00010 Helix-loop-helix DNA-binding domain
Function

Transcriptional regulator (lacking a basic DNA binding domain) which negatively regulates the basic helix-loop-helix (bHLH) transcription factors by forming heterodimers and inhibiting their DNA binding and transcriptional activity. Implicated in regulating a variety of cellular processes, including cellular growth, senescence, differentiation, apoptosis, angiogenesis, and neoplastic transformation. Inhibits skeletal muscle and cardiac myocyte differentiation. Regulates the circadian clock by repressing the transcriptional activator activity of the CLOCK-ARNTL/BMAL1 heterodimer. Restricts the CLOCK and ARNTL/BMAL1 localization to the cytoplasm. Plays a role in both the input and output pathways of the circadian clock: in the input component, is involved in modulating the magnitude of photic entrainment and in the output component, contributes to the regulation of a variety of liver clock-controlled genes involved in lipid metabolism.

> Gene Ontology
 
Biological Process GO:0000082 G1/S transition of mitotic cell cycle
GO:0000083 regulation of transcription involved in G1/S transition of mitotic cell cycle
GO:0001503 ossification
GO:0001649 osteoblast differentiation
GO:0001655 urogenital system development
GO:0001656 metanephros development
GO:0001779 natural killer cell differentiation
GO:0001822 kidney development
GO:0001966 thigmotaxis
GO:0002262 myeloid cell homeostasis
GO:0002521 leukocyte differentiation
GO:0002573 myeloid leukocyte differentiation
GO:0002683 negative regulation of immune system process
GO:0002694 regulation of leukocyte activation
GO:0002695 negative regulation of leukocyte activation
GO:0002761 regulation of myeloid leukocyte differentiation
GO:0002763 positive regulation of myeloid leukocyte differentiation
GO:0003007 heart morphogenesis
GO:0003013 circulatory system process
GO:0003149 membranous septum morphogenesis
GO:0003161 cardiac conduction system development
GO:0003164 His-Purkinje system development
GO:0003166 bundle of His development
GO:0003205 cardiac chamber development
GO:0003206 cardiac chamber morphogenesis
GO:0003229 ventricular cardiac muscle tissue development
GO:0003231 cardiac ventricle development
GO:0003279 cardiac septum development
GO:0003281 ventricular septum development
GO:0007050 cell cycle arrest
GO:0007346 regulation of mitotic cell cycle
GO:0007507 heart development
GO:0007568 aging
GO:0007569 cell aging
GO:0007622 rhythmic behavior
GO:0007623 circadian rhythm
GO:0007626 locomotory behavior
GO:0008015 blood circulation
GO:0008217 regulation of blood pressure
GO:0008344 adult locomotory behavior
GO:0009314 response to radiation
GO:0009416 response to light stimulus
GO:0009648 photoperiodism
GO:0009649 entrainment of circadian clock
GO:0010001 glial cell differentiation
GO:0010035 response to inorganic substance
GO:0010038 response to metal ion
GO:0010226 response to lithium ion
GO:0010720 positive regulation of cell development
GO:0010721 negative regulation of cell development
GO:0014003 oligodendrocyte development
GO:0014013 regulation of gliogenesis
GO:0014014 negative regulation of gliogenesis
GO:0014015 positive regulation of gliogenesis
GO:0014706 striated muscle tissue development
GO:0019216 regulation of lipid metabolic process
GO:0021537 telencephalon development
GO:0021700 developmental maturation
GO:0021772 olfactory bulb development
GO:0021782 glial cell development
GO:0021988 olfactory lobe development
GO:0030098 lymphocyte differentiation
GO:0030099 myeloid cell differentiation
GO:0030101 natural killer cell activation
GO:0030183 B cell differentiation
GO:0030218 erythrocyte differentiation
GO:0030225 macrophage differentiation
GO:0030278 regulation of ossification
GO:0030279 negative regulation of ossification
GO:0030534 adult behavior
GO:0030879 mammary gland development
GO:0030900 forebrain development
GO:0032844 regulation of homeostatic process
GO:0032846 positive regulation of homeostatic process
GO:0032922 circadian regulation of gene expression
GO:0033002 muscle cell proliferation
GO:0033598 mammary gland epithelial cell proliferation
GO:0034101 erythrocyte homeostasis
GO:0035239 tube morphogenesis
GO:0042063 gliogenesis
GO:0042113 B cell activation
GO:0042752 regulation of circadian rhythm
GO:0043153 entrainment of circadian clock by photoperiod
GO:0043353 enucleate erythrocyte differentiation
GO:0043392 negative regulation of DNA binding
GO:0043433 negative regulation of sequence-specific DNA binding transcription factor activity
GO:0044708 single-organism behavior
GO:0044770 cell cycle phase transition
GO:0044772 mitotic cell cycle phase transition
GO:0044843 cell cycle G1/S phase transition
GO:0045165 cell fate commitment
GO:0045444 fat cell differentiation
GO:0045475 locomotor rhythm
GO:0045577 regulation of B cell differentiation
GO:0045578 negative regulation of B cell differentiation
GO:0045598 regulation of fat cell differentiation
GO:0045600 positive regulation of fat cell differentiation
GO:0045619 regulation of lymphocyte differentiation
GO:0045620 negative regulation of lymphocyte differentiation
GO:0045637 regulation of myeloid cell differentiation
GO:0045639 positive regulation of myeloid cell differentiation
GO:0045646 regulation of erythrocyte differentiation
GO:0045648 positive regulation of erythrocyte differentiation
GO:0045649 regulation of macrophage differentiation
GO:0045651 positive regulation of macrophage differentiation
GO:0045665 negative regulation of neuron differentiation
GO:0045667 regulation of osteoblast differentiation
GO:0045668 negative regulation of osteoblast differentiation
GO:0045685 regulation of glial cell differentiation
GO:0045686 negative regulation of glial cell differentiation
GO:0045687 positive regulation of glial cell differentiation
GO:0045777 positive regulation of blood pressure
GO:0045786 negative regulation of cell cycle
GO:0045787 positive regulation of cell cycle
GO:0048469 cell maturation
GO:0048511 rhythmic process
GO:0048512 circadian behavior
GO:0048537 mucosal-associated lymphoid tissue development
GO:0048541 Peyer's patch development
GO:0048546 digestive tract morphogenesis
GO:0048557 embryonic digestive tract morphogenesis
GO:0048562 embryonic organ morphogenesis
GO:0048565 digestive tract development
GO:0048566 embryonic digestive tract development
GO:0048568 embryonic organ development
GO:0048659 smooth muscle cell proliferation
GO:0048660 regulation of smooth muscle cell proliferation
GO:0048661 positive regulation of smooth muscle cell proliferation
GO:0048663 neuron fate commitment
GO:0048667 cell morphogenesis involved in neuron differentiation
GO:0048708 astrocyte differentiation
GO:0048709 oligodendrocyte differentiation
GO:0048710 regulation of astrocyte differentiation
GO:0048711 positive regulation of astrocyte differentiation
GO:0048713 regulation of oligodendrocyte differentiation
GO:0048715 negative regulation of oligodendrocyte differentiation
GO:0048732 gland development
GO:0048738 cardiac muscle tissue development
GO:0048872 homeostasis of number of cells
GO:0050673 epithelial cell proliferation
GO:0050768 negative regulation of neurogenesis
GO:0050769 positive regulation of neurogenesis
GO:0050864 regulation of B cell activation
GO:0050865 regulation of cell activation
GO:0050866 negative regulation of cell activation
GO:0050869 negative regulation of B cell activation
GO:0051090 regulation of sequence-specific DNA binding transcription factor activity
GO:0051098 regulation of binding
GO:0051100 negative regulation of binding
GO:0051101 regulation of DNA binding
GO:0051249 regulation of lymphocyte activation
GO:0051250 negative regulation of lymphocyte activation
GO:0051961 negative regulation of nervous system development
GO:0051962 positive regulation of nervous system development
GO:0055123 digestive system development
GO:0060411 cardiac septum morphogenesis
GO:0060412 ventricular septum morphogenesis
GO:0060537 muscle tissue development
GO:0060612 adipose tissue development
GO:0060644 mammary gland epithelial cell differentiation
GO:0060749 mammary gland alveolus development
GO:0061030 epithelial cell differentiation involved in mammary gland alveolus development
GO:0061031 endodermal digestive tract morphogenesis
GO:0061180 mammary gland epithelium development
GO:0061351 neural precursor cell proliferation
GO:0061377 mammary gland lobule development
GO:0061448 connective tissue development
GO:0071156 regulation of cell cycle arrest
GO:0071158 positive regulation of cell cycle arrest
GO:0071241 cellular response to inorganic substance
GO:0071248 cellular response to metal ion
GO:0071285 cellular response to lithium ion
GO:0071931 positive regulation of transcription involved in G1/S transition of mitotic cell cycle
GO:0072001 renal system development
GO:0090068 positive regulation of cell cycle process
GO:0090398 cellular senescence
GO:1901987 regulation of cell cycle phase transition
GO:1901990 regulation of mitotic cell cycle phase transition
GO:1902105 regulation of leukocyte differentiation
GO:1902106 negative regulation of leukocyte differentiation
GO:1902107 positive regulation of leukocyte differentiation
GO:1902806 regulation of cell cycle G1/S phase transition
GO:1903706 regulation of hemopoiesis
GO:1903707 negative regulation of hemopoiesis
GO:1903708 positive regulation of hemopoiesis
GO:2000045 regulation of G1/S transition of mitotic cell cycle
GO:2000177 regulation of neural precursor cell proliferation
GO:2000178 negative regulation of neural precursor cell proliferation
Molecular Function GO:0044325 ion channel binding
Cellular Component GO:0005813 centrosome
> KEGG and Reactome Pathway
 
KEGG hsa04350 TGF-beta signaling pathway
hsa04390 Hippo signaling pathway
hsa04550 Signaling pathways regulating pluripotency of stem cells
Reactome -
Summary
SymbolID2
Nameinhibitor of DNA binding 2, dominant negative helix-loop-helix protein
Aliases GIG8; bHLHb26; cell growth-inhibiting gene 8; GIG8A; ID2H; DNA-binding protein inhibitor ID2; class B basic ......
Chromosomal Location2p25
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between ID2 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between ID2 and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
27678219MelanomaPromote immunity (T cell function)Vaccination with ID2-GM-DCs slowed the progression of melanoma tumors and enhanced animal survival, which was associated with an increased abundance of tumor-infiltrating interferon-γ-positive CD4(+) effector and CD8(+) cytotoxic T cells and a decreased number of tumor-infiltrating regulatory CD4(+) T cells. The efficacy of the ID2-GM-DC vaccine was improved by combinatorial treatment with a blocking antibody to programmed cell death protein-1 (PD-1), a current immunotherapy that overcomes suppressive immune checkpoint signaling. Collectively, our data reveal a previously unrecognized STAT3-mediated immunosuppressive mechanism in DCs and indicate that DC-intrinsic ID2 promotes tumor immunity by modulating tumor-associated CD4(+) T cell responses. Thus, inhibiting STAT3 or overexpressing ID2 selectively in DCs may improve the efficiency of DC vaccines in cancer therapy.
29866045Small Cell Lung CarcinomaInhibit immunityAlso, ID2 was differentially regulated between SCLC and LUSC, with its up-regulation in SCLC linking to energy supply for fast mitosis and its down-regulation in LUSC linking to the attenuation of immune response.
29866045Squamous Cell Lung CarcinomaPromote immunityAlso, ID2 was differentially regulated between SCLC and LUSC, with its up-regulation in SCLC linking to energy supply for fast mitosis and its down-regulation in LUSC linking to the attenuation of immune response.
Summary
SymbolID2
Nameinhibitor of DNA binding 2, dominant negative helix-loop-helix protein
Aliases GIG8; bHLHb26; cell growth-inhibiting gene 8; GIG8A; ID2H; DNA-binding protein inhibitor ID2; class B basic ......
Chromosomal Location2p25
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of ID2 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolID2
Nameinhibitor of DNA binding 2, dominant negative helix-loop-helix protein
Aliases GIG8; bHLHb26; cell growth-inhibiting gene 8; GIG8A; ID2H; DNA-binding protein inhibitor ID2; class B basic ......
Chromosomal Location2p25
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of ID2 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.4310.31
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.9120.68
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.0880.96
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.7750.179
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.3230.835
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 471.3520.509
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-0.3590.425
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-0.0180.99
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.8330.635
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.0310.988
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.4150.896
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.0110.927
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of ID2 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27730001
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27590001
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91606.2-6.21
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59011.1-11.11
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38270001
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolID2
Nameinhibitor of DNA binding 2, dominant negative helix-loop-helix protein
Aliases GIG8; bHLHb26; cell growth-inhibiting gene 8; GIG8A; ID2H; DNA-binding protein inhibitor ID2; class B basic ......
Chromosomal Location2p25
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of ID2. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolID2
Nameinhibitor of DNA binding 2, dominant negative helix-loop-helix protein
Aliases GIG8; bHLHb26; cell growth-inhibiting gene 8; GIG8A; ID2H; DNA-binding protein inhibitor ID2; class B basic ......
Chromosomal Location2p25
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of ID2. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by ID2.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolID2
Nameinhibitor of DNA binding 2, dominant negative helix-loop-helix protein
Aliases GIG8; bHLHb26; cell growth-inhibiting gene 8; GIG8A; ID2H; DNA-binding protein inhibitor ID2; class B basic ......
Chromosomal Location2p25
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of ID2. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolID2
Nameinhibitor of DNA binding 2, dominant negative helix-loop-helix protein
Aliases GIG8; bHLHb26; cell growth-inhibiting gene 8; GIG8A; ID2H; DNA-binding protein inhibitor ID2; class B basic ......
Chromosomal Location2p25
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of ID2 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolID2
Nameinhibitor of DNA binding 2, dominant negative helix-loop-helix protein
Aliases GIG8; bHLHb26; cell growth-inhibiting gene 8; GIG8A; ID2H; DNA-binding protein inhibitor ID2; class B basic ......
Chromosomal Location2p25
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between ID2 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolID2
Nameinhibitor of DNA binding 2, dominant negative helix-loop-helix protein
Aliases GIG8; bHLHb26; cell growth-inhibiting gene 8; GIG8A; ID2H; DNA-binding protein inhibitor ID2; class B basic ......
Chromosomal Location2p25
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting ID2 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.